Literature DB >> 175089

The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.

F R DeRubertis, R Chayoth, J B Field.   

Abstract

Data from cultured cells have suggested that cyclic AMP and cyclic GMP may be important determinants of cell growth and transformation. However, few studies have examined cyclic nucleotide content and metabolism in naturally occurring tumors of man. Accordingly, in the present study we compared cAMP and cGMP levels and metabolism in carcinomas of the human colon to those of the adjacent uninvolved mucosa after therapeutic resection of these tissues. The cAMP content of the tumors, determined in samples frozen 30 min after excision, was significantly lower than that of the adjacent mucosa, when expressed on the basis of tissue wet weight, protein, or DNA content. By contrast, the cGMP content of the tumors was higher than that of the surrounding mucosa if calculated on the basis of tissue wet weight, but this difference did not persist when correction was made for the higher protein or DNA content of the tumors. Incubation of slices of mucosa or tumor with or without theophylline in vitro increased tissue cAMP and cGMP content above levels observed in frozen samples of the same tissue. However, after such incubations cAMP levels in the tumors remained clearly below that of the mucosa, while cGMP content of the two tissues did not differ. The failure of theophylline to abolish differences in cAMP content and the comparable activities of high and low Km cAMP-phosphodiesterase in homogenates of the two tissues suggested that the lower cAMP content of the tumors was a consequence of diminished cAMP synthesis rather than enhanced degradation. This possibility was supported by the reduction in basal and maximal prostaglandin E1 (PGE1)-responsive adenylate cyclase activity found in tumor homogenates relative to those of mucosa, and the lower levels of cAMP in tumor slices after incubation of the tissues with a maximal dose of PGE1 and theophylline. Since NaF-responsive adenylate cyclase activity was not significantly reduced in the tumors, the lower basal and PGE1 activities may not be related to a deficiency of the catalytic unit of the cyclase complex in this tissue. The role of reduced activity of the adenylate cyclase-cAMP system and/or reduced tissue cAMP-to-cGMP ratios in the pathogenesis of colonic carcinoma is uncertain, but these changes might favor unregulated cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 175089      PMCID: PMC436697          DOI: 10.1172/JCI108320

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Cyclic AMP and cyclic GMP content and binding in malignancy.

Authors:  M L Goldberg; G C Burke; H P Morris
Journal:  Biochem Biophys Res Commun       Date:  1975-01-20       Impact factor: 3.575

2.  Cyclic AMP and cyclic GMP concentrations in serum- and density-restricted fibroblast cultures.

Authors:  W Moens; A Vokaer; R Kram
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

3.  Cyclic AMP modulates microvillus formation and agglutinability in transformed and normal mouse fibroblasts.

Authors:  M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

4.  Evidence for persistent binding of biologically active thyrotropin to thyroid in vitro.

Authors:  F R DeRubertis; R Chayoth; U Zor; J B Field
Journal:  Endocrinology       Date:  1975-06       Impact factor: 4.736

5.  Cyclic adenosine 3':5'-monophosphate and the induction of deoxyribonucleic acid synthesis in liver.

Authors:  J Short; K Tsukada; W A Rudert; I Lieberman
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

6.  Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).

Authors:  R A Hickie; C M Walker; A Datta
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

7.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

8.  Rapid calculation of radioimmunoassay results.

Authors:  D Rodbard; W Bridson; P L Rayford
Journal:  J Lab Clin Med       Date:  1969-11

9.  Adenylate cyclase in intestinal crypt and villus cells: stimulation by cholera enterotoxin and prostaglandin E1.

Authors:  C J Schwartz; D V Kimberg; P Ware
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

10.  The influence of intracellular levels of cyclic nucleotides on cell proliferation and the induction of antibody synthesis.

Authors:  J Watson
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

View more
  15 in total

1.  Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture.

Authors:  M Laburthe; M Rousset; C Boissard; G Chevalier; A Zweibaum; G Rosselin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

2.  Nicotine decreases guanylate cyclase activity.

Authors:  D L Vesely; G S Levey
Journal:  Bull Environ Contam Toxicol       Date:  1978-07       Impact factor: 2.151

3.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

4.  Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).

Authors:  A J Claflin; D L Vesely; J L Hudson; C B Bagwell; D C Lehotay; T M Lo; M A Fletcher; N L Block; G S Levey
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

5.  The relation between cell proliferation and adenylate cyclase activity in grafts of 3-methylcholanthrene induced mouse uterine cervical tumors.

Authors:  S Kvinnsland; P E Lønning; J G Forsberg
Journal:  Experientia       Date:  1982-03-15

6.  Cyclic nucleotide levels in human breast cancer and in rat mammary tissues during tumor development.

Authors:  E Israeli; B Raz; H Kerner; D Barzilai
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.

Authors:  Haifeng Zhu; Jessica Tao Li; Fang Zheng; Emil Martin; Alexander Y Kots; Joshua S Krumenacker; Byung-Kwon Choi; Ian E McCutcheon; Norman Weisbrodt; Oliver Bögler; Ferid Murad; Ka Bian
Journal:  Mol Pharmacol       Date:  2011-09-09       Impact factor: 4.436

8.  Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.

Authors:  G A Turner; R D Ellis; D Guthrie; A L Latner; J M Monaghan; W M Ross; A W Skillen; R G Wilson
Journal:  J Clin Pathol       Date:  1982-08       Impact factor: 3.411

9.  Testosterone and its precursors and metabolites enhance guanylate cyclase activity.

Authors:  D L Vesely
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

10.  Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors.

Authors:  P K Heinonen; T Metsä-Ketelä
Journal:  Med Oncol Tumor Pharmacother       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.